1.775 billion! Domestic cardiovascular industry leading enterprises by Carlyle brand

"Pharmaceutical Network Industry Dynamics" September 1 evening news, the domestic cardiovascular industry leader Xinlitai by Carlyle Group, the latter to buy a 5% stake in Xinlitai.
the announcement issued by Xinlitai, Carlyle was offered more than 52.3 million shares at a price of 33.94 yuan per share, with a total share transfer price of about 1,775 million yuan.
public information shows that Xinlitai was founded in 1998, listed on the Shenzhen Stock Exchange in 2009, the main business involves pharmaceutical, medical device products research and development, production, sales, the main products and research projects including cardiovascular drugs and medical devices, cephalospora antibiotics and raw materials, orthopaedic drugs.
the first half of 2020, Xinlitai reported revenue of RMB1,536 million, down 34.81% YoY, and net profit attributable to shareholders of listed companies was RMB197 million, down 68.92% YoY. the
announcement explained that this was mainly affected by the outbreak, as well as the company's heavy product hydrochlorochlorocarbon greas tablets in the "4 plus 7" most cities and Fujian And hebei Province after the renewal of the bid significantly reduced prices, its net profit impact.
it is worth mentioning that the company's research and development pipeline is rich, has now entered the cash period.
drug perspective, the first class 1.1 antihypertensive new drug, Alysatan esters, was added to medicare in 2019 to achieve rapid release.
in the study of products, phase III clinical 1 and I./II. phase 6 clinical.
, on August 31st, the Insight database showed that Xinlitai had initiated Phase I clinical recombinant glucagoglycline-like peptide-1-Fc fusion protein injection (SAL015).
the drug as a biosynthrobial for blood sugar control in patients with type 2 diabetes.
In addition, in the first half of 2020, the company's heart failure-resistant JK07 Sino-American double report is conducting Phase I clinical trials in the United States;
In the industry's view, China's pharmaceutical market is entering a sustained and stable long-term growth cycle as society ages and consumption levels rise, health awareness increases, and biotechnology continues to innovate.
increased consumer demand for high-quality, cost-effective and innovative products, as well as further consolidation of the generics market, companies with high-quality generic and innovative drug research and development capabilities in the pharmaceutical industry are expected to gain greater market opportunities.
cardiovascular disease is a major killer of human health.
, according to the 2019 China Cardiovascular Report 2018 released by the National Cardiovascular Center, the number of cardiovascular diseases in China is currently as high as 290 million, approaching 300 million people.
behind the huge data, will attract more enterprise layout, market competition will be more intense.
, according to Xinlitai's announcement, the two sides will combine their respective advantages to help Xinlitai Pharmaceuticals develop into a global innovative pharmaceutical company.
Specific cooperation includes four aspects: first, the use of Carlyle's international vision of experts and consultants resources to help Xinlitai's international business layout;
group was founded in the United States in 1987 and has long been known in the investment community as the "President's Club".
data show that Carlyle has invested in more than 80 projects in the field of health care, with a total equity investment of more than $13.4 billion, including third-party independent medical testing agency Addison, global peptide API manufacturer Ambo, high-tech medical equipment manufacturer Micro-Invasion Healthcare, medical giant Sino-American Medical and so on.
as of June 30 this year, Carlyle had invested in more than 100 projects in China with a total equity investment of more than $9.5 billion.